BRCA1, Ki67, and -Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

Autor(es)

Sallum, Luis Felipe ^[1] ; Andrade, Liliana ^[2] ; Eloy da Costa, Larissa Bastos ^[2] ; Ramalho, Susana ^[1] ; Ferracini, Amanda Canato ^[3] ; Natal, Rodrigo de Andrade ^[4] ; Carvalho Brito, Angelo Borsarelli ^[5] ; Sarian, Luis Otavio ^[1] ; Derchain, Sophie ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Rua Tessalia Vieira de Camargo 126, BR-13083970 Sao Paulo - Brazil

^[2] Univ Estadual Campinas, Dept Pathol, Fac Med Sci, Sao Paulo - Brazil

^[3] Univ Estadual Campinas, Fac Med Sci, Program inMed Sci, Sao Paulo - Brazil

^[4] Univ Estadual Campinas, Fac Med Sci, Lab Invest & Mol Pathol, Sao Paulo - Brazil

^[5] Univ Estadual Campinas, Fac Med Sci, Canc Genet Lab, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: International Journal of Gynecological Cancer; v. 28, n. 3, p. 437-447, MAR 2018.
• Citações Web of Science: 2

Resumo

Objective The purpose of this study was to compare the immunohistochemical expression of BRCA1, Ki67, and -catenin in women with low-grade (LGSOC) and high-grade serous ovarian carcinomas (HGSOC) and their relationship with clinicopathological features, response to platinum-based chemotherapy, and survival. Methods For this study, 21 LGSOC and 85 HGSOC stage I to IV cases, diagnosed and treated from 1996 to 2013 and followed-up until December 2016, were included. BRCA1, Ki67, and -catenin expression was assessed using tissue microarray-based immunohistochemistry. Results Women with HGSOC were significantly more likely to have advanced-stage disease (P < 0.001), higher CA125 levels (P < 0.001), postsurgery residual disease (P < 0.01), and higher rates of disease progression and recurrence (P = 0.001). The percentage of women with HGSOC whose tumors expressed Ki67 was significantly higher compared with women with LGSOC (P < 0.001). The expression of BRCA1 and -catenin did not differ between LGSOC and HGSOC (P = 0.12 and P = 1.00, respectively). The clinicopathological features and the response to platinum-based chemotherapy did not differ according to the BRCA1, Ki67, and -catenin expression in either group. In HGSOC, only International Federation of Gynecology and Obstetrics stage was independently associated with poor survival (PFS and OS). Conclusions Ki67 expression was significantly higher in HGSOC. BRCA1 and -catenin expression did not differ between LGSOC and HGSOC samples. BRCA1, Ki67, and -catenin expression was neither related to clinicopathological features, response to platinum-based chemotherapy, nor survival. Only International Federation of Gynecology and Obstetrics stage remained associated with poor survival in women with HGSOC. (AU)

• Processo FAPESP: 12/15059-8 - Avaliação de biomarcadores para detecção de neoplasia maligna em mulheres com tumor anexial
• Beneficiário: Sophie Françoise Mauricette Derchain
• Modalidade de apoio: Auxílio à Pesquisa - Regular